Condition (MeSH)
Embolic Stroke
ClinicalTrials.gov lists 35 trials for Embolic Stroke or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
35 of the 35 trials are tagged with Embolic Stroke itself; the rest are tagged with a narrower condition beneath it.
When did Embolic Stroke trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 4 |
| 2021 | 1 |
| 2020 | 3 |
| 2019 | 2 |
| 2018 | 4 |
| 2017 | 2 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 35 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Embolic Stroke trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 4 | 3 |
| Not applicable | 4 |
| Observational | 25 |
How many Embolic Stroke trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 4 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 2 |
| Completed | 13 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Embolic Stroke trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Ischemia Care LLC | 2 |
| Moleac Pte Ltd. | 2 |
| Lifetech Scientific (Shenzhen) Co., Ltd. | 1 |
Which drugs are being tested for Embolic Stroke? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| LOVENOX | 1 |
| Dabigatran | 1 |
| Acenocoumarol | 1 |
| Edoxaban | 1 |
| (LMW)heparin | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| MLC1501 | 2 |
| hirudin plus aspirin | 1 |
| Aspirin and Clopidogrel | 1 |
| Warfarin VKA | 1 |
| Shuxuetong Injection | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Embolic Stroke trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Myocardial Infarction | 2 | 1 |
| Pneumonia | 2 | 1 |
| Symptomatic Sinus Bradycardia | 2 | 1 |
| Atrial Fibrillation | 1 | 1 |
| Bacterial peritonitis | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Embolic Stroke? (40)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Current Therapy for Carotid Webs. | Annals of vascular surgery | 2025 | Yes |
| Aspirin plus rivaroxaban efficacy and safety in embolic stroke of undetermined source: A randomized, placebo-controlled, outcome assessor-blind, feasibility study. | Clinical neurology and neurosurgery | 2025 | Yes |
| A multi-center study on the predictors of different subtypes of hemorrhagic transformation of brain infarction after thrombolysis in atrial fibrillation patients presented with embolic stroke. | Scientific reports | 2025 | Yes |
| Outcomes of Patients With Embolic Stroke of Undetermined Source Treated With Antiplatelet Agents or Anticoagulation: A Multicenter Cohort Study. | Neurology | 2025 | Yes |
| Insights into the vascular aging burden in young adults with embolic stroke of undetermined source. | Journal of the neurological sciences | 2025 | Yes |
Showing 5 of 40 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.